The authors also showed that the prostate cancer risk ratio was further reduced (OR, 0.64) per 10 ng/mL increase in serum selenium among men with high-grade prostate cancer carrying the rs1050450 variant T allele, while no such risk modifications were observed with increasing serum selenium with the GPX1 rs1050450 dominant allele C. This evidence concerns the gene GPX1 and prostate carcinoma.